HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cosmetic Regulation Update's Link With OTC Drug User Fees Clear At Hearing

This article was originally published in The Rose Sheet

Executive Summary

Members of the House Health Subcommittee suggest their support for potential OTC monograph reform legislation depends on including provisions that would add substantial details to FDA's oversight of cosmetics manufacturers and a related user fee program.

You may also be interested in...

OTC Monograph Reform Momentum Carries Potential Exclusivity Snag

Support was unanimous during House Health Subcommittee markup for draft legislation on streamlining FDA's monograph system by eliminating public rulemakings from the process and allowing the agency to make decisions with administrative orders. Two-year exclusivity for some products didn't go over so well.

Rose Report Podcast – September 2017

Rose Sheet’s editorial team counts down top news items in the cosmetics and dietary supplement sectors over the past month, including possible cosmetics regulatory convergence under a renegotiated NAFTA, the FTC’s first enforcement action against social media influencers, FDA movement to develop a list of “old dietary ingredients” pre-dating DSHEA, and more.

No Authorization For OTC Monograph Reform And User Fees, But Webinar Goes On

FDA’s Aug. 23 webinar will update industry stakeholders on progress to modernize its OTC monograph program, but without user fee legislation, new performance goals will not take effect; stakeholders hold out hope a standalone OTC user fee bill could still progress in Congress.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts